GIST, short for gastrointestinal stromal tumor, is a type of cancer that develops in the walls of the digestive tract. It’s relatively rare, affecting roughly 10 to 15 people per million worldwide, with about 5,000 new cases diagnosed each year in the United States. Unlike more common GI cancers that start in the lining of the stomach or intestines, GISTs grow from specialized cells embedded deeper in the digestive wall.
Where GISTs Come From
GISTs originate from cells called the interstitial cells of Cajal, or from shared precursor cells. These cells act as pacemakers for your digestive system, coordinating the rhythmic contractions that move food through your gut. When the genes controlling their growth malfunction, these cells can multiply unchecked and form a tumor.
The stomach is the most common location, followed by the small intestine. Less frequently, GISTs appear in the esophagus, colon, or rectum. In rare cases they develop outside the GI tract entirely, in surrounding tissues of the abdomen.
The Genetic Mutations Behind GIST
Most GISTs are driven by a mutation in one of two genes. About 61% carry a mutation in the KIT gene, and roughly 25% have a mutation in a related gene called PDGFRA. Both mutations cause a protein on the cell surface to stay permanently switched on, sending nonstop growth signals. This is important because it makes GISTs targetable with specific drugs designed to block those signals.
The remaining 10 to 15% of GISTs lack mutations in either KIT or PDGFRA. These “wild-type” tumors are a mixed bag genetically. Some involve deficiencies in cellular energy-processing pathways, while others carry mutations in genes tied to broader growth-signaling networks. A small number have no identifiable mutation at all. Wild-type GISTs tend to behave differently and often need a different treatment approach.
Symptoms and How GISTs Are Found
GIST symptoms are frustratingly vague. The most common complaints include general abdominal discomfort, feeling full after eating very little, and GI bleeding that may be obvious or so subtle it only shows up as anemia on a blood test. Larger tumors sometimes create a mass you or a doctor can feel through the abdomen.
Because these symptoms overlap with dozens of other conditions, 15 to 30% of GISTs are discovered by accident during imaging, surgery, or even autopsy performed for unrelated reasons. Small GISTs in particular can sit quietly for years without causing noticeable problems.
How GISTs Are Diagnosed
Imaging (usually a CT scan) can identify a suspicious mass, but confirming a GIST requires examining tissue under a microscope. Pathologists look for two key markers. The first, called CD117, is a protein produced by the KIT gene and is present in about 85% of GISTs. The second, DOG-1, has a sensitivity of 89% and a specificity near 95%, meaning it catches most GISTs while rarely flagging something that isn’t one. Using both markers together allows pathologists to confidently diagnose GISTs, including the subset that lack KIT mutations.
Genetic testing of the tumor tissue itself has become standard practice. Knowing exactly which mutation is driving the tumor helps doctors choose the most effective targeted therapy and predict how the cancer is likely to behave.
Determining How Aggressive a GIST Is
Not all GISTs carry the same risk. Doctors classify them using a risk stratification system based on a few key factors:
- Tumor size. Tumors larger than 5 cm carry significantly higher recurrence risk.
- Mitotic rate. This measures how fast cells are dividing. More than 5 dividing cells per microscopic field signals a more aggressive tumor.
- Location. GISTs outside the stomach, particularly those in the small intestine or rectum, tend to recur more often than gastric GISTs of the same size.
- Tumor rupture. If the tumor broke open before or during surgery, recurrence risk rises substantially.
A small, slow-growing stomach GIST might be classified as very low risk, while a large, rapidly dividing small-intestine GIST would fall into the high-risk category. This classification directly shapes decisions about whether additional treatment is needed after surgery.
Surgery as the Primary Treatment
For GISTs that haven’t spread, surgical removal is the main treatment. The goal is to remove the entire tumor with clean margins. Unlike many other cancers, GISTs rarely spread to lymph nodes, so extensive lymph node removal is typically unnecessary. For very small, low-risk tumors, surgery alone may be the only treatment needed.
After surgery, patients in the intermediate or high-risk categories are usually offered targeted drug therapy to reduce the chance of recurrence. This adjuvant treatment has been shown to extend both recurrence-free survival and overall survival.
Targeted Therapy for GIST
GISTs respond poorly to traditional chemotherapy. What transformed GIST treatment was the development of drugs that directly block the overactive proteins driving tumor growth. The first-line drug, imatinib, is taken as a daily pill. For most patients, the standard dose is 400 mg per day. Patients whose tumors carry a specific KIT mutation (in a region called exon 9) often need double that dose to achieve the same benefit.
When imatinib stops working, usually because the tumor develops new mutations that bypass the drug’s effect, a clear sequence of alternatives exists. Sunitinib serves as second-line therapy, followed by regorafenib as a third option. In 2020, the FDA approved ripretinib as a fourth-line treatment for patients who have progressed through all three prior therapies.
That same year, a drug called avapritinib was approved specifically for patients with a particular PDGFRA mutation (D842V) that doesn’t respond to imatinib at all. This was a significant development because that mutation had previously left patients without an effective targeted option.
Follow-Up After Treatment
GISTs can recur years after initial treatment, so long-term monitoring is essential. For patients who have had surgery, guidelines recommend abdominal and pelvic CT scans every 3 to 6 months. Patients with very low-risk tumors can be scanned less frequently. This schedule continues for years because late recurrences, while less common, do happen. The most typical sites for recurrence are the liver and the lining of the abdominal cavity, which is why imaging focuses on those areas.